MedTrace Logo

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

NCT03119194 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-08-24

No results posted yet for this study

Summary

The purpose is to and to assess the mass balance recovery after a single oral dose of \[14C\]-BIA 9-1067 and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.

Conditions

  • Parkinson Disease

Interventions

DRUG

[14C]-BIA 9-1067

1 × 100 mg capsule, Oral

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-27
Primary Completion
2017-04-27
Completion
2017-04-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119194 on ClinicalTrials.gov